Most Clicked StoriesMore >


FDA has approved 35 new drugs this year, surpassing 2013 levels

BIO SmartBrief | Dec 17, 2014

Thirty-five new drugs, including 15 orphan drugs, have been approved by the FDA so far this year compared with 27 for all of last year, according to FDA Commissioner Margaret Hamburg. Fifty-seven percent of the approved drugs held priority-review status while 37% were granted fast-track designation. Medical Marketing & Media (12/15)


Drugs for unmet needs would get 15-year data exclusivity under Senate bill

BIO SmartBrief | Dec 16, 2014

Lilly drug gets FDA nod to treat lung cancer

BIO SmartBrief | Dec 15, 2014

Why comparative trials are a double-edged sword

BIO SmartBrief | Dec 17, 2014

Janssen gains rights to Halozyme's drug delivery platform

BIO SmartBrief | Dec 18, 2014

Senate bill aims to boost access to new antibiotics

BIO SmartBrief | Dec 15, 2014

Novartis invests $10M in Israeli drugmaker

BIO SmartBrief | Dec 17, 2014

Pfizer licenses OPKO's GHD treatment in deal that could surpass $570M

BIO SmartBrief | Dec 16, 2014

Prostate cancer drug developer gets $8M from investors

BIO SmartBrief | Dec 15, 2014

Huntington's chorea drug from Auspex hits main goal in trial

BIO SmartBrief | Dec 17, 2014


Find BIO SmartBrief Issues by Date:



BIO News More >


Registration is open for the BIO CEO & Investor Conference!

BIO SmartBrief | Dec 19, 2014

Faster & better connections with quality R&D vendors

BIO SmartBrief | Dec 18, 2014

Industrial biotechnology with a French twist!

BIO SmartBrief | Dec 17, 2014

Fall 2014 BIO Therapeutic Newsletters

BIO SmartBrief | Dec 15, 2014

New BIO Survey Tool: FDA/Sponsor Interactions During Drug Development

BIO SmartBrief | Dec 08, 2014




Sign up for BIO SmartBrief



Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more